FDA Guidance 2026: New August Updates Could Change How Sponsors Plan Generics, Biosimilars and CMC Programs
FDA’s August 2026 guidances update therapeutic equivalence, ANDA vs 505(b)(2), container closure systems and drug-development expectations.
FDA’s August 2026 guidances update therapeutic equivalence, ANDA vs 505(b)(2), container closure systems and drug-development expectations.